Relevance of donor-specific antibody monitoring after kidney transplantation

• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Aykut, Güçlü [VerfasserIn]
• Verfasst von: Morath, Christian [VerfasserIn]
• Verfasst von: Fichtner, Alexander [VerfasserIn]
• Verfasst von: Unterrainer, Christian [VerfasserIn]
• Verfasst von: Scherer, Sabine [VerfasserIn]
• Verfasst von: Tran, Thuong Hien [VerfasserIn]
• Verfasst von: Mehrabi, Arianeb [VerfasserIn]
• Verfasst von: Zeier, Martin [VerfasserIn]
• Verfasst von: Tönshoff, Burkhard [VerfasserIn]
• Titel: Relevance of donor-specific antibody monitoring after kidney transplantation
• Titelzusatz: findings from the Collaborative Transplant Study and the Heidelberg Transplant Center
• Verf.angabe: Caner Süsal, Güclü Aykut, Christian Morath, Alexander Fichtner, Christian Unterrainer, Sabine Scherer, Thuong H. Tran, Arianeb Mehrabi, Martin Zeier, Burkhard Tönshoff
• E-Jahr: 2019
• Jahr: 12 August 2019
• Umfang: 5 S.
• Fussnoten: Gesehen am 09.04.2020
• Titel Quelle: Enthalten in: HLA
• Ort Quelle: Oxford : Wiley, 2016
• Jahr Quelle: 2019
• Band/Heft Quelle: 94(2019), S2, Seite 11-15
• ISSN Quelle: 2059-2310
• DOI: doi:10.1111/tan.13665
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: antibody-mediated rejection
• Sach-SW: C1q
• Sach-SW: donor-specific antibodies
• Sach-SW: graft rejection
• Sach-SW: graft survival
• Sach-SW: kidney transplantation
• Sach-SW: sCD30
• Sach-SW: tacrolimus
• Sach-SW: under-immunosuppression
• K10plus-PPN: 1694316602
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitoring in patients undergoing renal transplantation. The obtained findings underline the importance of DSA monitoring in the post-operative course in immunologically high-risk patients and patients with deterioration of graft function. Especially in patients with a pre-activated immune system, a gap in the immunosuppressive therapy appear to lead to persistence, reappearance or de novo occurrence of strong, complement-activating DSA, resulting in severe antibody-mediated rejection (AMR) and, without timely intervention, in AMR-related graft loss.